Work

A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-8233

Authors: Hoda Pourhassan, Jianying Zhang, Wendy Stock, Mark Geyer, Anjali Advani, Jae Park, Emily Curran, Katrin Tiemann, Vaibhav Agrawal, Paul Koller, Jose Tinajero, Tibor Kovacsovics, Anthony Selwyn Stein, Guido Marcucci, Melisa Stricherz, Stefan Faderl, Vinod Pullarkat, Ibrahim Aldoss

Institutions: City Of Hope National Medical Center, University of Chicago, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, University of Cincinnati, City of Hope, Jazz Pharmaceuticals (Ireland)

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417015337

Cites:

Cited by:

Related to: